Navigation Links
PPD Names VPs for North America and Asia

Expands global senior leadership team; restructures business units


WILMINGTON, N.C., Oct. 10 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointments of Paul D. Colvin as senior vice president of clinical operations for North America and Simon J. Britton as vice president of clinical operations for Asia.

Mr. Colvin joins PPD from Eli Lilly and Company where he most recently directed clinical operations and global patient enrollment optimization. During his 14-year career at Lilly, he held a series of leadership positions including chief operations officer for the global cardiovascular brand team; European clinical operations senior manager for the oncology, critical care, primary care and neuroscience business units; global clinical operations manager for oncology project teams; and clinical project management leader for the oncology project team.

"Paul Colvin brings extensive global development experience across a wide range of therapeutic areas garnered during an impressive tenure with Lilly," said William Sharbaugh, chief operating officer of PPD. "His experience as a leader in the trenches of clinical drug development will serve him well in overseeing our North American Phase II-IV operational unit."

The position assumed by Mr. Britton is a new senior management role created specifically for the company's business on that continent.

"With Asia's escalating importance to global drug development, additional leadership will enable us to drive PPD's continued growth in the region," Mr. Sharbaugh said. "We are pleased to gain Simon Britton as a member of our team with his comprehensive international experience and proven ability to expand business scope and deliver quality results."

Mr. Britton spent the last seven years at GlaxoSmithKline where he most recently served as head of international clinical operations, managing the company's global clinical operations group across 25 countries. He brings more than 16 years' experience in leadership roles in the biopharmaceutical industry.

With Mr. Britton's appointment, PPD has divided its Phase II-IV operational units into four distinct territories: North America; Latin America; Europe, Middle East and Africa (EMEA); and Asia.

"This strategic restructuring of our business units geographically will enhance our ability to leverage PPD talent globally, strengthen internal standardization of our processes and further our ability to manage complex multinational trials efficiently," Mr. Sharbaugh added.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 29 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employees' performance and value to PPD as well as the geographic restructuring, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; success in sales growth; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



Louise Caudle

+919 456 4467


Steve Smith

+910 558 7585

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. Rise In Obesity Among North Qeenslanders
11. Northfield Labs Receives FDA Comments
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... at the 7th Annual 2015 Golden Bridge Business Awards under the New Products ... a zero capex web based sample management software that helps labs ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... Francisco, CA (PRWEB) , ... December 01, 2015 ... ... Behavioral Health Center of Excellence (BHCOE) today announced that the organization has awarded ... in San Francisco, with a Distinguished Award. The award celebrates exceptional special needs ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... today that the company will present at the LD Micro ... the Luxe Sunset Boulevard Hotel in Los Angeles, ... Therapeutics, will present on Thursday, December 3, at 9:00 am ... Please register at least 10 minutes prior to the start ...
Breaking Medicine Technology: